Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results

Savara (NASDAQ:SVRA) issued its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11), Zacks reports.

Savara Trading Down 9.4 %

SVRA traded down $0.36 during midday trading on Wednesday, hitting $3.47. The company’s stock had a trading volume of 2,023,397 shares, compared to its average volume of 1,206,000. Savara has a 52-week low of $3.28 and a 52-week high of $5.70. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $3.96 and a two-hundred day moving average price of $4.22. The firm has a market cap of $571.16 million, a P/E ratio of -8.24 and a beta of 1.02.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. HC Wainwright dropped their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday. Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Savara in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Savara currently has an average rating of “Moderate Buy” and an average target price of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.